Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-h8C3
- Development stage
- Unknown
- Lead developer
- Radimmune Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**177Lu-h8C3** is a radiopharmaceutical drug consisting of a monoclonal antibody (h8C3) conjugated with the radioactive isotope lutetium-177. It is designed for targeted radiotherapy, where the antibody binds to a specific antigen on tumor cells, delivering localized radiation via lutetium-177. The mechanism involves the selective internalization or binding of the antibody to tumor cell surface antigens, inducing cytotoxicity through beta-emission from 177Lu, resulting in DNA damage and cell death. This approach is a form of radioimmunotherapeutic, used as a targeted therapy for cancers expressing the relevant antigen. The specific antigen target and the developer details are not clearly specified in public databases, but such radiolabeled antibodies are typically explored for various solid tumors, including certain types of melanoma or other malignancies.
- Brand names
- 177Lu-h8C3
- Other names
- 177Lu-h8C3
02
Targets
MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on 177Lu-h8C3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-h8C3.